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Background/Aims
Lubiprostone, a chloride channel type 2 (ClC-2) activator, was thought to treat constipation by enhancing intestinal secretion. 
It has been associated with increased intestinal transit and delayed gastric emptying. Structurally similar to prostones with up 
to 54% prostaglandin E2 activity on prostaglandin E receptor 1 (EP1), lubiprostone may also exert EP1-mediated procontractile 
effect on intestinal smooth muscles. We investigated lubiprostone’s effects on intestinal smooth muscle contractions and py-
loric sphincter tone. 
Methods
Isolated murine small intestinal (longitudinal and circular) and pyloric tissues were mounted in organ baths with modified 
Krebs solution for isometric recording. Basal muscle tension and response to electrical field stimulation (EFS; 2 ms pulses/10 
V/6 Hz/30 sec train) were measured with lubiprostone (10
-10-10
-5 M) ± EP1 antagonist. Significance was established using 
Student  t test and P ＜  0.05. 
Results
Lubiprostone had no effect on the basal tension or EFS-induced contractions of longitudinal muscles. With circular muscles, 
lubiprostone caused a dose-dependent increase in EFS-induced contractions (2.11 ± 0.88 to 4.43 ± 1.38 N/g, P = 0.020) 
that was inhibited by pretreatment with EP1 antagonist  (1.69 ± 0.70 vs. 4.43 ± 1.38 N/g, P = 0.030). Lubiprostone had 
no effect on circular muscle basal tension, but it induced a dose-dependent increase in pyloric basal tone (1.07 ± 0.01 to 
1.97 ± 0.86 fold increase, P ＜  0.05) that was inhibited by EP1 antagonist. 
Conclusions
In mice, lubiprostone caused a dose-dependent and EP1-mediated increase in contractility of circular but not longitudinal small 
intestinal smooth muscles, and in basal tone of the pylorus. These findings suggest another mechanism for lubiprostone’s ob-
served clinical effects on gastrointestinal motility. 
(J Neurogastroenterol Motil 2013;19:312-318)
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Introduction
Lubiprostone, a chloride channel type 2 (ClC-2) activator, 
has been approved for the treatment of chronic constipation and 
constipation-predominant irritable bowel. Prior clinical study 
performed in healthy volunteers showed that lubiprostone is asso-
ciated with increased intestinal transit, increased fasting gastric 
volume and delayed gastric emptying.
1 The proposed primary 
mechanism of action of lubiprostone in the gastrointestinal tract is 
increased chloride ion transport into the intestinal lumen caused 
by opening of ClC-2, leading to increased intestinal secretion and 
enhanced mass transit.
2,3 Nausea is the most common side effect 
of lubiprostone, reported in up to 31% of patients in one study.
5 
Several possible explanations for nausea have been suggested, in-
cluding delayed gastric emptying, small intestinal distention sec-
ondary to increased gastric secretion, change in gastrointestinal 
sensation, or additional actions of lubiprostone on gastrointestinal 
motility.
1 However, the underlying mechanism of nausea asso-
ciated with lubiprostone remains unclear. In addition, lubipro-
stone has been shown to accelerate overall colonic transit without 
significantly changing the rate of ascending colon emptying.
2 
With the proximal colon likely reabsorbing the increased fluid 
load from the small intestine, it was postulated that a primary mo-
tor effect on the colon beyond the ascending portion may be re-
sponsible for this finding. Similarly, the presence of any possible 
direct smooth muscle effect of lubiprostone on the rest of the gas-
trointestinal tract has been suggested. In fact, a recent study has 
shown that lubiprostone increased contraction of rat and human 
stomach longitudinal muscle, an action that was inhibited by 
prostaglandin E receptor 1 (EP1) antagonist.
6 Such effects may 
also be responsible for the clinical effect of lubiprostone such as 
nausea seen in humans.
Although lubiprostone is structurally similar to prostone, a 
bicyclic fatty acid compound derived from prostaglandin E1 
(PGE1) its level of interaction with E-type prostanoid receptors 
and the possible resultant clinical effect are not completely clear. 
While prior studies have suggested that lubiprostone only has 
very weak activity on prostaglandin receptors, it has also been re-
ported to have up to 54% PGE2 activity on EP1.
7 Recent studies 
have suggested that lubiprostone may also exert prostaglandin ef-
fects on non-gastrointestinal tissues.
8 Given lubiprostone’s struc-
tural similarity to prostone, reported activity on EP1, and effect 
on intestinal transit, we postulated that it may have direct procon-
tractile effects on both phasic and tonic smooth muscles in the 
small intestine, possibly involving EP1 activation. In this study, 
we investigated the effect of lubiprostone on the basal tone and 
neuronally-stimulated contraction of the phasic intestinal smooth 
muscle and the tonic pyloric sphincter muscle in mice. We also 
studied the possible interaction of lubiprostone on EP1 using a 
specific antagonist. 
Materials and Methods
Tissue Isolation and Preparation
Ten adult wild-type mice were sacrificed by carbon dioxide 
asphyxiation followed by cervical dislocation. All efforts were 
made to minimize the number of animals used. Immediately after 
death of the mice, a midline incision was made exposing the peri-
toneal cavity and contents. The stomach and entire small intestine 
were excised. The tissues were placed immediately in a pre-mixed 
Krebs solution (118 mM NaCl, 4.8 mM KCI, 1.2 mM KH2PO4, 
1.2 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3 and 11 
mM glucose), which was previously equilibrated with 5% CO2 in 
O2 at a temperature of 37
oC. The pylorus was isolated and 1 cm 
transverse sections of the small intestine were obtained. The mu-
cosa was left intact. The tissues were thoroughly flushed with the 
Krebs solution to remove any remaining food or bile. 
For small intestine, longitudinal muscles were isolated by us-
ing 1 cm length segments of small intestinal tissues. Both ends of 
the longitudinal muscles were attached to ring clips that were 
mounted on the isometric force transducers. For circular smooth 
muscles, the small intestinal tissues were cut into smaller trans-
verse segments of 0.2-0.3 cm width. The muscle ring prep was 
then mounted on the force transducers allowing measurement of 
circular muscle contraction. The pyloric tissues were similarly 
mounted in a ring prep fashion of approximately 0.5 cm in width 
for measurement of basal tone.
Tissue Bath Experiment
Isolated small intestinal (longitudinal and circular) and py-
loric sphincter tissues were mounted in 5 mL organ baths with 
Krebs solution for isometric recording. The Krebs solution was 
maintained in the organ baths by bubbling with 5% CO2/95% O2 
at 37
oC. Isometric force transducers measured changes in muscle 
tension of the tissues. Tissue samples were suspended under 4 
mN tension for isometric recording between 2 platinum ring 
electrodes. This preload was noted to be in the appropriate range 
of optimal electrical field stimulation (EFS)- and carbachol-in-Walter W Chan and Hiroshi Mashimo
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Figure 1. Sample tracing demonstrating increasing electrical field 
stimulation-induced contractions of intestinal circular smooth muscle 
with increasing concentrations of lubiprostone. EFS, electrical field 
stimulation.
Figure 2. Electrical field stimulation induced contractions of the 
circular smooth muscle demonstrated a dose-response relationship with 
increasing concentrations of lubiprostone (no antagonist). The addition 
of the prostaglandin E receptor 1 (EP1) antagonist, SC19220, atte-
nuated the lubiprostone-induced response in muscle contractions. EFS, 
electrical field stimulation.
duced contractions. The EFS parameters were chosen from prior 
experiments
9 that demonstrated tetrodotoxin-inhibitable neuro-
genic responses. For this experiment, peak contraction responses 
were achieved using 30 seconds train of biphasic square-wave 
pulses of 2 ms pulse width at 10 volts and frequency of 6 Hz. 
Baseline measurement was then taken with EFS stimulation in 
the absence of lubiprostone. Sequential addition of escalating 
doses of lubiprostone (0.0001-10 μM) was then performed to 
construct a cumulative concentration-response curve for neuro-
nally-stimulated smooth muscle contraction. Similar lubiprostone 
concentration-response curve for EFS-stimulated smooth muscle 
contraction was constructed in the presence of EP1 antagonist 
(SC19220; Sigma, Saint Louis, MO, USA) to evaluate the in-
volvement of the EP1 cascade in the lubiprostone-mediated 
smooth muscle contraction response. 
In a separate set of experiments, the basal tone of the smooth 
muscle of small intestines and the pylorus were studied in the ab-
sence of EFS. By similarly suspending tissue samples under 4 
mN for isometric recording in 5 mL wells of bubbling Krebs sol-
ution, the basal muscle tone of the muscles in response to escalat-
ing concentration of lubiprostone were recorded. At the end of 
the experiment, the tissues were placed on a slide and dried in an 
oven for obtaining dry weight. Tension measurements were nor-
malized for the mass of tissue. 
Data Acquisition and Analysis
Data acquisition and analysis was performed using the 
LabChart v. 7.0 software (ADInstruments, Colorado Springs, 
CO, USA). In the EFS experiments, the difference between the 
maximal muscle tension post-EFS stimulation and the minimal 
muscle tension pre-EFS stimulation was calculated for baseline 
and each lubiprostone concentration. This change in muscle ten-
sion pre- and post-EFS stimulation represents the EFS-medi-
ated pro-contractile response. In experiments for basal tone with-
out the use of EFS, the maximal muscle tension reached with 
each lubiprostone concentration was used. The muscle tension 
was normalized for the dry weight of the tissue used in each 
experiment. All data are expressed as means ± standard error of 
mean. Statistical significance was established using two-tailed 
Student’s t test and P ＜ 0.05. 
Chemical Reagents Used
All drugs were freshly prepared before use. Lubiprostone was 
extracted using a 24 gauge needle directly from commercially avail-
able 24 microgram capsules and suspended in 100% ethanol solu-
tion. Different concentrations of lubiprostone were obtained by fur-
ther dilution with 100% ethanol. The EP1 antagonist (SC19220; 
Sigma) was dissolved in pre-synthesized Krebs solution.
Ethical Approval
This study was approved by the VA Health System Institu-




In the measurement of EFS-stimulated smooth muscle con-
tractions, lubiprostone induces a dose-dependent increase in cir-Lubiprostone Induces EP1-mediated Contraction
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Figure 4. Longitudinal smooth muscle tone of the small intestine 
demonstrated no significant changes with increasing concentrations of 
lubiprostone.
Figure 5. Neuronal contractions of the longitudinal smooth muscles as 
simulated by electrical field stimulation showed no response to increa-
sing concentrations of lubiprostone. 
Figure 3. Basal circular smooth muscle tone of the small intestine did 
not show any significant differences with increasing concentrations of 
lubiprostone.
cular muscle contraction (range: 2.11 ± 0.88 N/g tissue to 4.43 
± 1.38 N/g tissue, n = 5, P = 0.020). Pretreatment with 1 μM 
EP1-RA SC19220 inhibits the enhanced circular muscle con-
traction induced by lubiprostone (4.43 ± 1.38 N/g tissue at 10 
μM lubiprostone vs. 1.69 ± 0.70 N/g tissue with EP1 antago-
nist, P = 0.030) (Fig. 1 and 2). The addition of SC19220 alone 
without lubiprostone did not result in any significant difference in 
EFS-stimulated circular muscle contraction from baseline. This 
suggests that the observed antagonistic effect of SC19220 on lu-
biprostone action was not due to a direct effect of SC19220 on 
muscle contraction. No effect was observed of lubiprostone on 
the basal tension of the circular muscles, as the basal muscle ten-
sion remained the same despite increasing concentrations of lubi-
prostone (range: 0.96 to 0.99 times baseline muscle tension, P = 
0.95) (Fig. 3). 
Longitudinal Muscles
In the study of small intestinal longitudinal muscles, adding 
lubiprostone exerted no effect on the basal muscle tension. The 
muscle tension measured at incremental concentrations of lubi-
prostone ranged from 0.99 to 1.03 times of muscle tension at base-
line (P = 0.480) (Fig. 4). Addition of 1 μM EP1 antagonist 
SC19220 also induced no change in the muscle tension measured. 
Stimulation of smooth muscle contraction by EFS with increas-
ing concentrations of lubiprostone yielded similar results, with 
the measured contractions ranging from 0.91 ± 0.46 N/g tissue 
to 1.10 ± 0.57 N/g tissue (n = 5, P = 0.998) (Fig. 5). 
Pyloric Sphincter
The basal tone of the pyloric sphincter (n = 5) demonstrated 
dose-dependent increase with the addition of escalating doses of 
lubiprostone (range: 1.07 ± 0.01 to 1.97 ± 0.96 times baseline 
tension, P ＜ 0.01). Pretreatment with 1 μM EP1 antagonist 
SC19220 inhibits the enhanced pyloric tone induced by lubipro-
stone (1.97 ± 0.96 times baseline tension at 10 μM lubiprostone 
vs. 1.16 ± 0.09 times baseline tension with EP1 antagonist, P ＜ 
0.01) (Fig. 6). 
Discussion
Lubiprostone is a PGE1 derivative which has been approved 
for the treatment of chronic constipation and constipation-pre-Walter W Chan and Hiroshi Mashimo
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Figure 6. The pyloric sphincter tone revealed a mild, significant increase 
in basal tone with lubiprostone. This increase in tone was inhibited by the 
prostaglandin E receptor 1 (EP1) antagonist SC19220. 
dominant irritable bowel. Its proposed primary mechanism of ac-
tion is an increase in chloride ion transport into the intestinal lu-
men caused by opening of the novel ClC-2 chloride channels, 
leading to increased intestinal secretion and enhanced mass 
transit. One of the promoted characteristics of lubiprostone is its 
specificity for ClC-2 and lack of systemic prostaglandin effects, 
despite its structural similarity to prostones. As shown in pre-
viously published studies, activation of E-type prostanoid re-
ceptors by PGE is associated with smooth muscles contractions 
in the gastrointestinal tract. The structural similarity of lubipro-
stone to PGE1 and the known procontractile action of PGE1 on 
certain smooth muscles led us to hypothesize that lubiprostone 
may also have direct gastrointestinal smooth muscle actions con-
tributing to its clinical effects. 
Our study has focused on the study of small intestinal and 
pyloric sphincter smooth muscles, 2 physiologically different 
types of smooth muscle. Small intestinal longitudinal and circular 
muscles are both phasic muscle. Phasic contractions are charac-
terized by rapid contraction and relaxation. Rhythmic phasic con-
tractions of intestinal smooth muscle generate peristalses that 
propel food through the gastrointestinal tract. On the other hand, 
the pyloric sphincter is an example of tonic muscle. Contrary to 
phasic contractions, tonic contractions are slow and sustained. 
Relaxation of the sustained tonic contractions leads to the open-
ing of the sphincter that allows passage of chyme from stomach to 
the duodenum. Lubiprostone may exert different effects on the 
various types of smooth muscles, resulting in the clinical profile 
of the medication. 
As lubiprostone treats constipation by reducing intestinal 
transit time, we hypothesized that it may also have a procon-
tractile effect on the phasic intestinal smooth muscles. Using 
EFS to simulate neuronal stimulation, our study demonstrated 
that lubiprostone indeed increases the circular smooth muscle 
contractions in a dose-dependent manner, while it has no effect 
on the longitudinal muscles. The disparity in the response of 
these muscles is consistent with the known mechanism of pro-
pulsion of intestinal contents, which requires coordinated but re-
ciprocal activities of longitudinal and circular muscles during 
peristalsis.
10 With each peristalsis, circular muscles contract oral 
and relax caudal to the site of stimulation, and longitudinal mus-
cles contract and relax in reverse to circular muscles to provide 
the coordinated forward propulsion. Therefore, longitudinal 
muscles exert ascending relaxation and descending contraction 
with each peristalsis. With these physiological properties of in-
testinal smooth muscles, our results can explain another mecha-
nism for the accelerated intestinal transit caused by lubiprostone 
besides the volume transit through its effect on ClC-2. The en-
hancement of contractions in one type of muscles (circular) cou-
pled with the lack of effect in the other (longitudinal) by lubipro-
stone could result in stronger forward propulsive force.
Our study has also shown that the procontractile effect on cir-
cular smooth muscle tension observed may have been achieved 
through an EP1-mediated pathway, as pretreatment with an EP1 
antagonist attenuated the procontractile effect of lubiprostone. 
Previous studies have demonstrated that PGE2 and its different 
receptor subtypes exert varying effects on gastrointestinal motili-
ty.
11,12 In particular, in a study of circular smooth muscles isolated 
from pig and guinea-pig ileum, EP1 agonist enhances contraction 
of the muscle cells.
11 EP1 are G protein-coupled receptors that 
regulate Ca
2+-channel gating
13 and they have been shown to in-
crease Ca
2+ concentration in Chinese hamster ovary cells without 
detectable phosphatidylinositide response.
14 Enhanced smooth 
muscle contractions, therefore, may be induced by EP1 via 
changes in intracellular Ca
2+ concentrations of smooth muscle 
cells. While different subtypes of PGE2 receptors are present in 
varying concentrations throughout the gastrointestinal tract, EP1 
have been detected in the muscularis mucosa, enteric glial cells, 
and smooth muscle layers of the small intestine.
15-17 Therefore, 
the increased muscular contractions by lubiprostone could be a 
result of effects on muscle or glial cells. Prior studies have sug-
gested roles for enteric glial cells in neurotransmission by media-
ting intercellular Ca
2+ waves
18 and muscular contraction by in-
creasing intracellular Ca
2+ concentration.
19 Clinical studies of pa-Lubiprostone Induces EP1-mediated Contraction
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tients with severe, chronic, slow-transit constipation demonstrate 
a loss of enteric glial cells and interstitial cells of Cajal,
20 but the 
specific roles of these cells in EP1-mediated contraction remains 
poorly characterized. The lubiprostone-mediated increase in cir-
cular muscle contractions during EFS observed in this study may 
have resulted from activation of EP1 located on either muscle or 
enteric glial cells.
In the study of pyloric muscles, lubiprostone increased the 
basal tone of the pyloric sphincter in a dose-dependent manner. 
This procontractile effect was attenuated by pretreatment with an 
EP1 antagonist, suggesting that the lubiprostone acted through 
an EP1-mediated pathway. Prior studies have demonstrated the 
presence of EP1 in the mucosal and smooth muscle layers of the 
gastric body and antrum.
15,16 However, the existence of EP1 or 
other PGE2 receptors in the pylorus remains unclear. Our results 
demonstrated the likely presence of EP1 on pyloric tissues and 
the possible effect of activation of the EP1 pathway. These phar-
macologic effects will need to be confirmed on human tissues.
One of the main side effects of lubiprostone is nausea, which 
may affect up to a third of the patients. The underlying mecha-
nism of lubiprostone-induced nausea is unclear. However, sev-
eral possible processes have been suggested, including delayed 
gastric emptying, small intestinal distention from increased gas-
tric secretion, change in gastrointestinal sensation, or alteration of 
gastrointestinal motility. The elevation of basal pyloric sphincter 
tone caused by lubiprostone may contribute to the nausea symp-
toms by delaying gastric emptying or in the form of pylorospasm. 
The resultant nausea may be particularly pronounced as lubipro-
stone increases gastric secretion through the activation of chloride 
channels. Gastric distention from decreased pyloric outflow and 
increased gastric secretion may produce nausea symptoms, espe-
cially in those with decreased compliance of the gastric wall.
Our results are significant in demonstrating prostaglandin- 
like actions of lubiprostone in the gastrointestinal tract, in addi-
tion to its known specific chloride channel effects. It is now less 
clear whether the clinical effects observed in patients with con-
stipation result predominantly from activation of ClC-2, as for-
merly believed, or from its prostaglandin-like effects on intestinal 
smooth muscles. Recent evidence suggests that lubiprostone acts 
predominantly on the classical cystic fibrosis transmembrane con-
ductance regulator (CFTR), and no chloride secretion could be 
observed using rectal epithelial cells from a patient homozygous 
for defective (F580del) CFTR.
21 In contrast, lubiprostone has 
been demonstrated in a recent case series to relieve constipation in 
patients with cystic fibrosis.
22 Thus the clinical benefit seen in 
these patients with defective CFTR may be related to lubipro-
stone’s action on EP1, as demonstrated by our results. Therefore, 
the general mechanisms of lubiprostone in relieving constipation 
may be multimodal.
Through understanding the underlying mechanism of lubi-
prostone effects, the newly described pathway of action for lubi-
prostone may open potential new use for the medication. For ex-
ample, patients with small intestinal pseudo-obstruction or ileus 
may respond to the procontractile effects of lubiprostone, while 
those with bile reflux may improve due to the increase in basal py-
loric sphincter tone. This may also enhance bicarbonate secretion 
and have cytoprotective effects, akin to misoprostol. On the other 
hand, potential negative consequences of PGE2 receptor activa-
tion should also be considered. Previous studies have demon-
strated that blockade of EP1 and EP4 inhibits the development of 
colon cancer in mouse models.
23,24 Given lubiprostone’s demon-
strated agonist effect on EP1, its chronic use may result in adverse 
consequence. Further studies are required to delineate lubipro-
stone’s other potential short- and long-term clinical effects result-
ing from its prostaglandin-like activities. Orally administered lu-
biprostone is rapidly metabolized, not only by the liver, but also 
immediately on the mucosal surface. Thus the intact compound is 
not detectable in the blood.
25 Therefore, it is possible that the ob-
served pro-contractile effects of lubiprostone are mediated by its 
metabolites. Also its primary site of action may be the mucosa, 
and not necessarily directly on the smooth muscles. To under-
stand lubiprostone’s actual clinical effect, we chose to study intact 
muscle preparation without inhibiting adrenergic or cholinergic 
effects and without removing the mucosa. Further mechanistic 
studies discerning its site of action, metabolites, and pathways 
would be warranted. Its interactions with other PGE2 receptor 
subtypes should also be explored. 
In conclusion, lubiprostone, previously described as a se-
lective chloride channel activator with little prostaglandin effect, 
caused a dose-dependent and EP1-mediated increase in con-
tractility of circular but not longitudinal small intestinal smooth 
muscles in mice. It had no effect on the basal tone of these phasic 
muscles. However, in the tonic pyloric sphincter, lubiprostone 
caused a dose-dependent increase in basal tone that was attenu-
ated by an EP1 antagonist. These findings suggest potential pros-
taglandin-like activities of lubiprostone. They also provide anoth-
er mechanism for the previously-reported accelerated intestinal 
transit and delayed gastric emptying in normal individuals given 
lubiprostone. Walter W Chan and Hiroshi Mashimo
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